New year, new hopes

Research output: Contribution to journalReview article

Abstract

This issue features one of the stunning advances in cancer care: imatinib, the prototype of the new wave of drugs that are rationally designed agents. Reports from the 2006 American Society of Hematology meeting confirmed the remarkable sustained effect of this drug and its followers dasatinib and nilotinib. Reports on these and other advances, critical to quality community care.

Original languageEnglish (US)
Number of pages1
JournalCommunity Oncology
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Quality of Health Care
Pharmaceutical Preparations
Neoplasms
Dasatinib
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

New year, new hopes. / Schwartzberg, Lee.

In: Community Oncology, Vol. 4, No. 1, 01.01.2007.

Research output: Contribution to journalReview article

@article{5009efab25324d8bacfef7f8082663ea,
title = "New year, new hopes",
abstract = "This issue features one of the stunning advances in cancer care: imatinib, the prototype of the new wave of drugs that are rationally designed agents. Reports from the 2006 American Society of Hematology meeting confirmed the remarkable sustained effect of this drug and its followers dasatinib and nilotinib. Reports on these and other advances, critical to quality community care.",
author = "Lee Schwartzberg",
year = "2007",
month = "1",
day = "1",
doi = "10.1016/S1548-5315(11)70011-0",
language = "English (US)",
volume = "4",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "1",

}

TY - JOUR

T1 - New year, new hopes

AU - Schwartzberg, Lee

PY - 2007/1/1

Y1 - 2007/1/1

N2 - This issue features one of the stunning advances in cancer care: imatinib, the prototype of the new wave of drugs that are rationally designed agents. Reports from the 2006 American Society of Hematology meeting confirmed the remarkable sustained effect of this drug and its followers dasatinib and nilotinib. Reports on these and other advances, critical to quality community care.

AB - This issue features one of the stunning advances in cancer care: imatinib, the prototype of the new wave of drugs that are rationally designed agents. Reports from the 2006 American Society of Hematology meeting confirmed the remarkable sustained effect of this drug and its followers dasatinib and nilotinib. Reports on these and other advances, critical to quality community care.

UR - http://www.scopus.com/inward/record.url?scp=33847789667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847789667&partnerID=8YFLogxK

U2 - 10.1016/S1548-5315(11)70011-0

DO - 10.1016/S1548-5315(11)70011-0

M3 - Review article

VL - 4

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 1

ER -